A phase i study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 547-554

  Bauman, Julie ^a   Verschraegen, Claire ^f   Belinsky, Steven ^b   Muller, Carolyn ^a   Rutledge, Teresa ^a   Fekrazad, M ^a   Ravindranathan, Meera ^c   Lee, Sang Joon ^d   Jones, Dennie ^e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c Hematology/Oncology   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF VERMONT   (United States)

Author keywords

5 azacytidine; Clinical trial; DNA methylation; Epidermal growth factor receptor; Epigenetic; Erlotinib; Phase I

Indexed keywords

AZACITIDINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COLON ADENOCARCINOMA; CONJUNCTIVITIS; DIARRHEA; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; INFECTION; INJECTION SITE REACTION; INTRADUCTAL CARCINOMA; KIDNEY CANCER; LARYNX CANCER; LARYNX CARCINOMA; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NAUSEA AND VOMITING; NEPHROBLASTOMA; NEUTROPENIA; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PAROTID GLAND CARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TASTE DISORDER; THROMBOCYTOPENIA; THYROID CARCINOMA; TONGUE CANCER; TREATMENT OUTCOME; URETER CANCER; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; VULVA CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; COHORT STUDIES; CONJUNCTIVITIS; DIARRHEA; DISEASE-FREE SURVIVAL; EXANTHEMA; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84856718345     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1729-2     Document Type: Article

References (28)

1. G Lurje H Lenz 2009 EGFR signaling and drug discovery Oncology 77 400 410 20130423 10.1159/000279388 1:CAS:528:DC%2BC3cXit1Ont70%3D
2. DS Salomon R Brandt F Ciardiello N Normanno 1994 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 10.1016/1040-8428(94)00144-I
3. CH Chung, et al. 2006 Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas JCO 24 25 4170 4176 10.1200/JCO.2006.07.2587 1:CAS:528: DC%2BD28XhtVantbvP (Pubitemid 46622295)
4. AW Hemming NL David A Kluftinger, et al. 1992 Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67 J Surg Oncol 51 147 152 1434639 10.1002/jso.2930510304 1:STN:280:DyaK3s%2FmtFSlsA%3D%3D
5. S Ueda S Ogata H Tsuda, et al. 2004 The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness; poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 29 e1 e8 15211117 10.1097/00006676-200407000-00061
6. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib NEJM 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
7. R Rosell T Moran C Queralt, et al. 2009 Screening for epidermal growth factor receptor mutations in lung cancer NEJM 361 1 10 10.1056/NEJMoa0904554
8. ER Camp J Summy TW Bauer, et al. 2005 Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor Clin Can Research 11 397 397 405 1:CAS:528:DC%2BD2MXhtVegtbw%3D (Pubitemid 40075820)
9. JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation NEJM 349 21 2042 2054 14627790 10.1056/NEJMra023075 1:CAS:528:DC%2BD3sXptFKmu7s%3D (Pubitemid 37448928)
10. PA Jones SB Baylin 2002 The fundamental role of epigenetic events in cancer Nat Rev 3 415 427 1:CAS:528:DC%2BD38XksFOmsrw%3D
11. L Shen H Kantarjian Y Gui, et al. 2010 DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes JCO 28 4 605 613 10.1200/JCO.2009.23.4781 1:CAS:528:DC%2BC3cXisVGgtbo%3D
12. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines) JNCI 92 205 216 10655437 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
13. GJ Rustin M Quinn T Thigpen, et al. 2004 New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) JNCI 96 6 487 488 15026475 (Pubitemid 38443654)
14. FA Shepherd JR Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small cell lung cancer NEJM 353 2 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
15. MH Cohen GA Williams R Sridhara G Chen R Pazdur 2003 FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 8 303 306 12897327 10.1634/theoncologist.8-4-303 1:CAS:528:DC%2BD3sXmvFSqtrc%3D (Pubitemid 36929716)
16. CE Vigil T Martins-Santos G Garcia-Manero 2010 Safety and efficacy of azacitidine in myelodysplastic syndromes Drug Des Dev Ther 4 221 229 10.2147/DDDT.S3143 1:CAS:528:DC%2BC3cXhtFyjs7nE
17. C Stresemann F Lyko 2008 Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int J Cancer 123 8 13 18425818 10.1002/ijc.23607 1:CAS:528:DC%2BD1cXmtlantrg%3D (Pubitemid 351705186)
18. PA Jones SM Taylor 1980 Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1 85 93 6156004 10.1016/0092-8674(80)90237-8 1:CAS:528:DyaL3cXksVamsrw%3D (Pubitemid 10117303)
19. SB Baylin 2005 DNA methylation and gene silencing in cancer Nat Clin Pract Oncol 2S 1 S4 S11 10.1038/ncponc0354 (Pubitemid 43135229)
20. SA Belinsky MJ Grimes MA Picchi, et al. 2011 Combination therapy with Vidaza and Entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model Cancer Res 71 2 454 462 21224363 10.1158/0008-5472.CAN-10-3184 1:CAS:528:DC%2BC3MXlsFKmug%3D%3D
21. Juergens R, Vendetti F, Wrangle J et al (2010) A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer. American Association for Cancer Research 101st Annual Meeting, 17-21 April 2010. Abstract LB-411
22. JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054 14627790 10.1056/NEJMra023075 1:CAS:528:DC%2BD3sXptFKmu7s%3D (Pubitemid 37448928)
23. SB Baylin JE Ohm 2006 Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6 107 116 16491070 10.1038/nrc1799 1:CAS:528:DC%2BD28Xht1eiurw%3D (Pubitemid 43361543)
24. SA Belinsky KJ Nikula WP Palmisano, et al. 1998 Aberrant methylation of p16 INK4a is an early event in lung cancer and a potential biomarker for early diagnosis Proc Natl Acad Sci USA 95 11891 11896 9751761 10.1073/pnas.95.20.11891 1:CAS:528:DyaK1cXmsV2hsbo%3D (Pubitemid 28460510)
25. Y Wang D Zhang W Zheng, et al. 2008 Multiple gene methylation of non-small cell lung cancers evaluated with 3-dimensional microarray Cancer 112 6 1325 1336 18286531 10.1002/cncr.23312 1:CAS:528:DC%2BD1cXksFKisr8%3D (Pubitemid 351429748)
26. WB Liu JY Liu L Ao, et al. 2010 Epigenetic silencing of cell cycle regulatory genes during 3-methyl cholanthrene and diethylnitrosamine-induced multistep rat lung cancer Mol Carcinog 49 6 556 565 20512841 1:CAS:528:DC%2BC3cXmslSrsrY%3D
27. R Noro A Gemma A Miyanaga, et al. 2007 PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors Int J Oncol 31 5 1157 1163 17912443 1:CAS:528:DC%2BD2sXhtlKhsrfF
28. MV Brock CM Hooker E Ota-Machida, et al. 2008 DNA methylation markers and early recurrence in stage I lung cancer NEJM 358 1118 1128 18337602 10.1056/NEJMoa0706550 1:CAS:528:DC%2BD1cXjt1aiurc%3D (Pubitemid 351398486)